Sign In
Buy GNLX
$2.95
-0.0200 (-0.673%)
At Close: Jun 02, 2026
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
07:01am, Friday, 13'th Dec 2024
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
04:01pm, Wednesday, 06'th Nov 2024
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and
Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point
10:59am, Thursday, 31'st Oct 2024
Topline results from phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer, are expected in the 2nd half of 2025. Interim data fr
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-sm
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
04:15pm, Wednesday, 09'th Oct 2024
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
04:01pm, Tuesday, 03'rd Sep 2024
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairma
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
04:05pm, Wednesday, 14'th Aug 2024
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024
07:00am, Tuesday, 30'th Jul 2024
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten o
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
04:01pm, Thursday, 23'rd May 2024
WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwr
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
04:25pm, Thursday, 09'th May 2024
WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
10:36am, Friday, 26'th Apr 2024
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
10:36am, Tuesday, 23'rd Apr 2024
The heavy selling pressure might have exhausted for Genelux Corporation (GNLX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
10:35am, Friday, 05'th Apr 2024
Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
01:02pm, Thursday, 04'th Apr 2024
Genelux Corporation (GNLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
